VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
KPTI
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
KPTIKaryopharm Therapeutics Inc.
$0.05$1M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksKPTIQuarterly Financials

Karyopharm Therapeutics Inc. (KPTI) Quarterly Income Statement

120+ quarters historyFree accessUpdated daily

Karyopharm Therapeutics Inc. (KPTI) quarterly income statement — complete revenue, gross profit & net income history

Income StatementBalance SheetCash FlowRatios

KPTI Income Statement

Quarterly statement

KPTI Income Statement

Karyopharm Therapeutics Inc. (KPTI) annual income statement — 15-year revenue, gross profit & net income history

AnnualQuarterly
MetricQ2'26Q1'26Q4'25Q3'25Q2'25Q1'25Q4'24Q3'24Q2'24Q1'24Q4'23Q3'23Q2'23Q1'23Q4'22Q3'22Q2'22Q1'22Q4'21Q3'21
Sales/Revenue33.43M35.07M34.08M44.04M37.93M30.02M30.54M38.78M42.79M33.13M33.75M36.01M37.58M38.7M33.58M36.15M39.68M47.67M126.27M37.69M
Revenue Growth %-11.86%16.83%11.58%13.57%-11.35%-9.39%-9.5%7.7%13.86%-14.4%0.5%-0.38%-5.29%-18.82%-73.41%-4.1%75.56%104.94%259.74%76.67%
Cost of Goods Sold1.08M1.36M1.48M2.11M1.05M1.3M1.33M1.3M1.56M2M1.56M911K1.19M1.35M1.87M980K939K1.43M742K589K
COGS % of Revenue3.25%3.87%4.35%4.8%2.77%4.33%4.36%3.35%3.64%6.03%4.63%2.53%3.18%3.49%5.56%2.71%2.37%2.99%0.59%1.56%
Gross Profit32.35M33.71M32.59M41.93M36.88M28.71M29.21M37.48M41.23M31.13M32.18M35.1M36.38M37.35M31.71M35.16M38.74M46.24M125.53M37.1M
Gross Margin %96.75%96.13%95.65%95.2%97.23%95.67%95.64%96.65%96.36%93.97%95.37%97.47%96.82%96.51%94.44%97.29%97.63%97.01%99.41%98.44%
Gross Profit Growth %-12.29%17.4%11.58%11.87%-10.56%-7.76%-9.24%6.8%13.32%-16.65%1.49%-0.19%-6.08%-19.24%-74.74%-5.22%80.5%107.12%268.68%77.55%
Operating Expenses54.87M60.47M50.44M57.15M61.27M61.97M60.49M63.77M69.35M64.89M69.99M66.36M65.96M68.25M65.58M66M81.65M80.83M78.56M80.91M
OpEx % of Revenue164.13%172.44%148.01%129.76%161.53%206.46%198.06%164.42%162.09%195.89%207.4%184.28%175.52%176.36%195.3%182.61%205.77%169.56%62.22%214.68%
Selling, General & Admin25.92M26.68M22.77M26.61M28.48M27.35M27.19M27.63M31.07M29.55M30.69M30.8M34.48M35.91M34.65M34.65M37.34M38.77M34.56M35.1M
SG&A % of Revenue77.52%76.1%66.82%60.41%75.08%91.13%89.02%71.25%72.62%89.2%90.94%85.55%91.76%92.79%103.18%95.85%94.1%81.33%27.37%93.14%
Research & Development29.95M33.78M27.67M30.54M32.79M34.62M33.3M36.13M38.28M35.34M39.3M35.55M31.48M32.34M30.93M31.36M44.31M42.06M44M45.81M
R&D % of Revenue89.57%96.35%81.18%69.35%86.45%115.34%109.04%93.17%89.47%106.68%116.47%98.73%83.76%83.57%92.11%86.76%111.67%88.24%34.85%121.54%
Other Operating Expenses-988K0000000000000000000
Operating Income-22.53M-26.76M-17.84M-15.22M-24.39M-33.26M-31.28M-26.28M-28.12M-33.76M-37.81M-31.26M-29.57M-30.9M-33.87M-30.84M-42.91M-34.59M46.96M-43.81M
Operating Margin %-67.38%-76.31%-52.36%-34.56%-64.3%-110.8%-102.42%-67.77%-65.72%-101.91%-112.03%-86.81%-78.7%-79.85%-100.86%-85.32%-108.14%-72.55%37.19%-116.25%
Operating Income Growth %7.63%19.53%42.96%42.09%13.28%1.49%17.26%15.92%4.91%-9.26%-11.63%-1.37%31.08%10.66%-172.12%29.61%12.52%33.96%226.7%7%
EBITDA-22.53M-26.75M-17.82M-15.1M-24.31M-33.18M-31.2M-26.2M-28.03M-33.67M-37.73M-31.18M-29.49M-30.61M-33.76M-30.66M-42.76M-34.41M47.1M-43.63M
EBITDA Margin %-67.39%-76.28%-52.3%-34.28%-64.09%-110.54%-102.15%-67.56%-65.51%-101.65%-111.81%-86.59%-78.47%-79.1%-100.52%-84.82%-107.76%-72.18%37.3%-115.75%
EBITDA Growth %7.32%19.38%42.87%42.37%13.27%1.47%17.31%15.97%4.95%-10.01%-11.78%-1.71%31.03%11.04%-171.67%29.73%12.41%34%227.96%6.93%
D&A (Non-Cash Add-back)-3K12K19K121K78K78K81K83K91K85K77K80K83K290K113K182K149K177K139K186K
EBIT-53.88M-9.84M-89.65M-22.64M-25.98M-12.43M-19.68M-20.66M32.81M-31.41M-35.5M-28.42M-26.72M-28.31M-32.55M-30.16M-42.63M-34.59M46.54M-43.7M
Net Interest Income-12.42M-12.04M-12.01M-10.46M-10.62M-9.99M-9.72M-9.55M-7.02M-3.73M-3.69M-3.32M-2.96M-2.91M-4.55M-5.46M-6.02M-6.61M-7.88M-7.91M
Interest Income722K511K607K553K613K1M1.48M1.83M1.93M2.16M2.52M2.75M2.82M2.85M1.33M658K293K74K55K98K
Interest Expense13.14M12.55M12.62M11.01M11.23M10.99M11.2M11.38M8.95M5.88M6.21M6.07M5.78M5.76M5.88M6.11M6.31M6.68M7.94M8.01M
Other Income/Expense-44.5M4.37M-84.42M-17.87M-12.82M9.83M392K-5.76M51.98M-3.53M-3.9M-3.23M-2.93M-3.17M-4.56M-5.44M-6.03M-6.68M-8.36M-7.89M
Pretax Income-67.02M-22.39M-102.27M-33.09M-37.21M-23.43M-30.89M-32.04M23.86M-37.29M-41.71M-34.49M-32.5M-34.07M-38.43M-36.28M-48.94M-41.27M38.6M-51.71M
Pretax Margin %-200.48%-63.85%-300.08%-75.14%-98.11%-78.05%-101.14%-82.62%55.76%-112.57%-123.59%-95.79%-86.49%-88.05%-114.45%-100.37%-123.34%-86.57%30.57%-137.19%
Income Tax01K-67K34K40K36K-109K28K67K71K130K12K127K54K73K45K121K130K-121K106K
Effective Tax Rate %0%-0%0.07%-0.1%-0.11%-0.15%0.35%-0.09%0.28%-0.19%-0.31%-0.03%-0.39%-0.16%-0.19%-0.12%-0.25%-0.32%-0.31%-0.21%
Net Income-67.02M-22.39M-102.2M-33.13M-37.25M-23.46M-30.78M-32.07M23.79M-37.36M-41.84M-34.51M-32.63M-34.13M-38.51M-36.32M-49.06M-41.4M38.72M-51.81M
Net Margin %-200.48%-63.86%-299.89%-75.21%-98.22%-78.17%-100.78%-82.7%55.61%-112.79%-123.97%-95.83%-86.83%-88.19%-114.67%-100.5%-123.65%-86.84%30.66%-137.47%
Net Income Growth %-79.92%4.56%-232.03%-3.29%-256.57%37.2%26.43%7.05%172.91%-9.48%-8.65%5%33.49%17.57%-199.45%29.89%8.44%27.89%189.17%3.15%
Net Income (Continuing)-67.02M-22.39M-102.2M-33.13M-37.25M-23.46M-30.78M-32.07M23.79M-37.36M-41.84M-34.51M-32.63M-34.13M-38.51M-36.32M-49.06M-41.4M38.72M-51.81M
Discontinued Operations00000000000000000000
Minority Interest00000000000000000000
EPS (Diluted)-2.32-1.24-5.69-3.82-4.32-2.772.81-3.85-2.97-4.85-5.47-4.52-0.29-4.51-0.43-0.45-0.62-0.530.46-0.69
EPS Growth %46.3%55.23%-302.49%0.78%-45.45%42.89%151.37%14.82%-924.14%-7.52%-1172.09%-904.44%53.23%-751.09%-193.48%34.78%12.68%31.17%177.97%93.68%
EPS (Basic)-2.32-1.02-15.16-3.82-4.32-2.772.81-3.85-3.79-4.85-5.47-4.52-0.29-4.51-0.43-0.45-0.62-0.530.51-0.69
Diluted Shares Outstanding28.94M24.71M18.21M8.67M8.62M8.47M8.39M8.33M10.29M7.7M7.65M7.63M114.21M7.57M89.93M80.21M79.65M77.57M86.88M75.46M
Basic Shares Outstanding28.94M22.01M6.74M8.67M8.62M8.47M8.39M8.33M8.07M7.7M7.65M7.63M114.21M7.57M89.93M80.21M79.65M77.57M75.67M75.46M
Dividend Payout Ratio--------------------